TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05350293

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Molded abutment
Description: The waxed plastic abutment will dismantle, wedged, and poured using a Ni-Cr mixture then it will be trimmed to make it ready to make the permanent restoration over it.~The prostheses will be cemented above the abutment using dual-cure resin cement then the final restoration (crown and abutment) will be fixed using a screw-retained manner.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D printed abutment
Description: A marker or Scan body appropriate for the type of implant will be placed on the laboratory implant substitute, a digital scan of the marker will be done in the lab, and the scanned image will be transferred to a computer design software where the prosthesis is designed, In the printing phase, the final prosthesis will be manufactured using a stepwise metal powder supply and a laser fusion process. Making the abutment ready to make the permanent restoration over it. The prostheses will be cemented above the abutment using dual-cure resin cement then the final restoration (crown and abutment) will be fixed using a screw-retained manner.
Study: NCT02774109

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil
Description: Five 1000mg fish oil soft capsules per day (each capsule containing 350mg EPA and 250mg DHA) for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Five 1000mg sunflower oil soft capsules per day for 8 weeks

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Hotpacking
Description: Hotpacking 15min on low back, three times a week for 8 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hotpacking
Description: Hotpacking 15min on low back, three times a week for 8 weeks

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Description: Transcutaneous electrical nerve stimulation (TENS) 15min on low back, three times a week for 8 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Description: Transcutaneous electrical nerve stimulation (TENS) 15min on low back, three times a week for 8 weeks
Study: NCT02444741

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo low dose radiation therapy
Study: NCT01169324

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alteration of DBS stimulator settings
Description: Alteration of DBS stimulator settings
Study: NCT01827904

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial ExAblate

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial ExAblate
Study: NCT01769794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Western therapy
Description: Physical cooling paste or warm bathing, vitamin B, vitamin C. On the basis of the attending physician's judgment, participants were allowed to use Ibuprofen suspension if their body temperature was greater than 38.5℃. Likewise, the need for antibiotics was determined by the attending physicians. The use of acetaminophen or antibiotics was recorded on the case record form

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Western therapy
Description: Physical cooling paste or warm bathing, vitamin B, vitamin C. On the basis of the attending physician's judgment, participants were allowed to use Ibuprofen suspension if their body temperature was greater than 38.5℃. Likewise, the need for antibiotics was determined by the attending physicians. The use of acetaminophen or antibiotics was recorded on the case record form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JET
Description: 4g/tablet, One tablet each time (Taken after dissolved in 50ml boiled water, 3 times daily if body temperature≥38.5℃)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo(for JET)
Description: placebos prepared identical in color, taste and consistency to the JET (supplied by Zhongshenghaitian Pharmaceutical, Tianjin, China)
Study: NCT02444741

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study: NCT02297724

Intervention type: OTHER
Intervention: Oxygen
Description: Administration of oxygen will last for no more than 10 min, with flow rate 15L/min via non-rebreather facial mask. Each subject will have once of the administration per scan.
Study: NCT03466788

Intervention type: OTHER
Group type: OTHER
Intervention: Self questionnaires of quality of life and living conditions
Description: Patients will complete self-questionnaires of living conditions and quality of life (QLQ-C30; EN24; CIPN20; IPAQ; HADS)

Intervention type: OTHER
Group type: OTHER
Intervention: Self questionnaires of quality of life and living conditions
Description: Patients will complete self-questionnaires of living conditions and quality of life (QLQ-C30; EN24; CIPN20; IPAQ; HADS)
Study: NCT00716027

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard behavioral treatment for weight loss
Description: A 24-week intervention in which individuals will meet weekly to be instructed on behavioral change associated with weight loss, including modifying dietary intake, self-monitoring weight and eating behaviors, and increasing physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified behavioral treatment for weight loss
Description: A 24-week intervention in which individuals will meet weekly to be instructed on behavioral change associated with weight loss, including modifying dietary intake, self-monitoring weight and eating behaviors, and increasing physical activity. In this intervention, individuals not meeting weight loss goals will be given one-on-one treatment.
Study: NCT02181842

Intervention type: DRUG
Intervention: Pioglitazone
Description: Pioglitazone tablets
Study: NCT01261962

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: zinc
Description: zinc sulfate, 35 mg twice daily for 4 months

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: zinc
Description: zinc sulfate, 35 mg twice daily for 4 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, One capsule, twice daily for 4 months

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Placebo, One capsule, twice daily for 4 months
Study: NCT02773641

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Saline Solution
Study: NCT00819091

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 1356
Description: 5mg orally (po) tablet qd

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching BI 1356 5mg one tablet daily
Study: NCT04160416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine-Oxaliplatin-Irinotecan Combination
Description: CAP 1,600 mg/sq.m /day (p.o. day1-10) D1-10; Oxaliplatin (OX): 68 mg/sq.m (d.i.v.) D1; Irinotecan (IRI):135 mg/sq.m (d.i.v.) D1; BEV: 5mg/kg (d.i.v.) D1; CET: 500 mg/sq.m (d.i.v.) D1; Administered every 2 weeks.
Study: NCT01432600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide at 4 mg by mouth (PO) as outlined in the treatment arms.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pomalidomide
Description: Pomalidomide at 4 mg by mouth (PO) as outlined in the treatment arms.
Study: NCT01835782

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-Serine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-Serine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-Serine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-Serine
Study: NCT02067403

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pressure-support Eadi optimization
Study: NCT01337245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Snake (Micrurus) North American immune F(ab')2 Equine
Description: 5 vials of study drug reconstituted and diluted to 250 mL Normal Saline and administered intravenously.
Study: NCT01432600

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pomalidomide
Description: Pomalidomide at 4 mg by mouth (PO) as outlined in the treatment arms.

Intervention type: DRUG
Group type: OTHER
Intervention: Pomalidomide
Description: Pomalidomide at 4 mg by mouth (PO) as outlined in the treatment arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone at 40 mg (20 mg) PO as outlined in the treatment arms.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone at 40 mg (20 mg) PO as outlined in the treatment arms.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone at 40 mg (20 mg) PO as outlined in the treatment arms.

Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone
Description: Dexamethasone at 40 mg (20 mg) PO as outlined in the treatment arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: The dose escalation uses a standard 3x3 design: Ex: If none of the first 3 participants have a DLT, enter 3 participants at the next higher dose level. Once the maximum tolerated dose (MTD) of oral weekly cyclophosphamide in combination with pomalidomide and dexamethasone was determined, investigators proceeded with the second phase of the trial, a randomized phase II study comparing pomalidomide and dexamethasone with pomalidomide, dexamethasone and oral weekly cyclophosphamide delivered at the MTD determined in the phase I study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: The dose escalation uses a standard 3x3 design: Ex: If none of the first 3 participants have a DLT, enter 3 participants at the next higher dose level. Once the maximum tolerated dose (MTD) of oral weekly cyclophosphamide in combination with pomalidomide and dexamethasone was determined, investigators proceeded with the second phase of the trial, a randomized phase II study comparing pomalidomide and dexamethasone with pomalidomide, dexamethasone and oral weekly cyclophosphamide delivered at the MTD determined in the phase I study.

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: The dose escalation uses a standard 3x3 design: Ex: If none of the first 3 participants have a DLT, enter 3 participants at the next higher dose level. Once the maximum tolerated dose (MTD) of oral weekly cyclophosphamide in combination with pomalidomide and dexamethasone was determined, investigators proceeded with the second phase of the trial, a randomized phase II study comparing pomalidomide and dexamethasone with pomalidomide, dexamethasone and oral weekly cyclophosphamide delivered at the MTD determined in the phase I study.
Study: NCT02851394

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levobupivacaine
Study: NCT04637217

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical Coherence Tomography
Description: Spectral Domain Optical Coherence Tomography(SD-OCT) examination will be performed for every patient: posterior pole scan, EDI-OCT(enhanced depth imaging-OCT) and peripapillary RNFL(retinal nerve fiber layer)

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical Coherence Tomography
Description: Spectral Domain Optical Coherence Tomography(SD-OCT) examination will be performed for every patient: posterior pole scan, EDI-OCT(enhanced depth imaging-OCT) and peripapillary RNFL(retinal nerve fiber layer)

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical Coherence Tomography
Description: Spectral Domain Optical Coherence Tomography(SD-OCT) examination will be performed for every patient: posterior pole scan, EDI-OCT(enhanced depth imaging-OCT) and peripapillary RNFL(retinal nerve fiber layer)
Study: NCT03494010

Intervention type: OTHER
Intervention: Observation
Description: There is no intervention. Patients will receive the HCL system as part of their clinical care.
Study: NCT00228449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide
Study: NCT00562848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK962040
Description: GSK962040 will be supplied in the following tablet strengths: 1 milligram, 5m milligrams, 25 milligrams, 125 milligrams.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK962040
Description: GSK962040 will be supplied in the following tablet strengths: 1 milligram, 5m milligrams, 25 milligrams, 125 milligrams.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK962040
Description: GSK962040 will be supplied in the following tablet strengths: 1 milligram, 5m milligrams, 25 milligrams, 125 milligrams.
Study: NCT03495700

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: L-PRF block
Description: The use of the L-PRF block as graft material for sinus augmentation procedure will be analysed

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DBBM
Description: The use of bovine xenograft will be analysed
Study: NCT00698607

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (Xience or Promus)
Description: Use everolimus-eluting stent in the treatment of coronary stenosis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (Xience or Promus)
Description: Use everolimus-eluting stent in the treatment of coronary stenosis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus-eluting stent (Cypher)
Description: Use sirolimus-eluting stent in the treatment of coronary stenosis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus-eluting stent (Cypher)
Description: Use sirolimus-eluting stent in the treatment of coronary stenosis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-month clopidogrel therapy
Description: Use clopidogrel for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6-month clopidogrel therapy
Description: Use clopidogrel for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12-month clopidogrel therapy
Description: Use clopidogrel for 12 months
Study: NCT00562848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive placebo.
Study: NCT04841395

Intervention type: DIAGNOSTIC_TEST
Intervention: Intravaginal ejaculatory latency time (IELT), Arabic Index of Premature Ejaculation (AIPE), Morningness-Eveningness Questionnaire (MEQ)
Description: Self-estimated intravaginal ejaculatory latency time IELT is defined as the time between the onset of vaginal intromission and the onset of intravaginal ejaculation. In the present research, self-estimated IELT duration was obtained as a result of interviews with the participants. Moreover, Arabic Index of Premature Ejaculation (AIPE), International Index of Erectile Function (IIEF-5), Pittsburgh Sleep Quality Index (PSQI) and Morningness-Eveningness Questionnaire (MEQ) were administered to all participants.

Intervention type: DIAGNOSTIC_TEST
Intervention: Intravaginal ejaculatory latency time (IELT), Arabic Index of Premature Ejaculation (AIPE), Morningness-Eveningness Questionnaire (MEQ)
Description: Self-estimated intravaginal ejaculatory latency time IELT is defined as the time between the onset of vaginal intromission and the onset of intravaginal ejaculation. In the present research, self-estimated IELT duration was obtained as a result of interviews with the participants. Moreover, Arabic Index of Premature Ejaculation (AIPE), International Index of Erectile Function (IIEF-5), Pittsburgh Sleep Quality Index (PSQI) and Morningness-Eveningness Questionnaire (MEQ) were administered to all participants.
Study: NCT00698607

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 12-month clopidogrel therapy
Description: Use clopidogrel for 12 months
Study: NCT03370627

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monoclonal anti-cd303 antibody
Description: Addition of monoclonal anti CD303 antibodies or not (control) on 2 blood samples of the same patient, to which 10 μl of CpG (20 μg / ml) are added in order to activate plasmacytoid Dendritic Cells and to induce the secretion of Type I interferons.
Study: NCT00228449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide
Study: NCT01345058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lacosamide
Description: Lacosamide maximum of 200 mg/day, to be titrated as follows:~* Week 1: 50 mg twice a day~* Beginning Week 2: 100 mg twice a day.

Intervention type: DRUG
Group type: OTHER
Intervention: levetiracetam
Description: Low dose ≤1500 mg/day, High dose \>1500 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levetiracetam
Description: Low dose ≤1500 mg/day, High dose \>1500 mg/day
Study: NCT02455908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proleukin®
Study: NCT03254537

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mediterranean Organic
Description: Traditional Mediterranean diet comprised of organic ingredients

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mediterranean conventional
Description: Traditional Mediterranean diet comprised of conventional ingredients
Study: NCT03113539

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Low-dose, EKG-gated CT without contrast for the evaluation of aortic aneurysm
Description: On the same day, the subject will do :~1. Modified low-dose, EKG-gated CT without contrast~2. Usual high-dose, EKG-gated CT with contrast~Comparing aortic diameters from the two protocols.
Study: NCT02838017

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tissue Adhesive

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sterile strips
Study: NCT04382794

Intervention type: DRUG
Intervention: Retrospective case-control analysis
Description: Evaluation of clinical, laboratory and instrumental parameters of diabetic patients during hospitalization for COVID-19. The data will be extracted anonymously from the computerized medical records commonly used in clinical practice by the centers involved in the study

Intervention type: DRUG
Intervention: Retrospective case-control analysis
Description: Evaluation of clinical, laboratory and instrumental parameters of diabetic patients during hospitalization for COVID-19. The data will be extracted anonymously from the computerized medical records commonly used in clinical practice by the centers involved in the study
Study: NCT03394924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-305 1 mg
Description: Two tablets daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-305 2.5 mg
Description: Two tablets daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two tablets daily for 12 weeks
Study: NCT04136938

Intervention type: OTHER
Intervention: Social marketing campaign
Description: A social marketing campaign of prevention workshop sessions will be performed.
Study: NCT01884350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Study: NCT01702129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-EGFR immunoliposomes loaded with doxorubicin
Description: All patients were treated with anti-EGFR immunoliposomes Different dose levels (5, 10, 20, 30, 40, 50 and 60 mg doxorubicin/m2), at least 3 patients per dose level, treatment was given every 4 weeks
Study: NCT04523129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CyclASol topical ocular, eye drops
Description: Cyclosporine A solution in vehicle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle topical ocular, eye drops
Description: Vehicle
Study: NCT03626181

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta Burst Stimulation ( Transcranial Magnetic Stimulation)
Description: Participants will receive bilateral TBS, 5 times daily (15 minutes between), over 5 consecutive days (25 sessions total). In each session they will receive intermittent TBS (iTBS) over left dorsolateral prefrontal cortex (DLPFC), followed by continuous TBS (cTBS) over right DLPFC. Stimulation sites will be targeted with the Localite neuronavigation system and Visor2 software, and according to Talairach coordinates in relation to individual MRIs. Intensity will be standardized at 120% of RMT.~The MagPro stimulator will deliver iTBS over left DLPFC with 1620 pulses in 54 triplet bursts (5Hz) with train duration of 2 seconds, and intertrain interval of 8 seconds. cTBS over right DLPFC will consist of 1620 pulses in 54 triplet bursts, train duration of 2 seconds, with no intertrain interval.
Study: NCT01830712

Intervention type: DRUG
Intervention: eptacog alfa (activated)
Description: A review of retrospectively longitudinal data gathered in the routine follow-up from a subset of patients who underwent EOS in studies F7HAEM/USA/3/USA and F7HAEM/USA/4/USA (NCT01561391). Data will be compiled, analysed, and reported in aggregate form.
Study: NCT02115373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib
Description: Participants received a single oral dose of Tepotinib 300 milligram (mg) in each 21 days treatment cycle until progressive disease, intolerable toxicity, death, or withdrawal from treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib
Description: Participants received a single oral dose of Tepotinib 500 mg daily in each 21 days treatment cycle until progressive disease, intolerable toxicity, death, or withdrawal from treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib
Description: Participants received a single oral dose of Tepotinib 500 mg daily in each 21 days treatment cycle until progressive disease, intolerable toxicity, death, or withdrawal from treatment.